



**NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT
THIRD QUARTER OF 2018 (2018Q3)**

**Substance Abuse Epidemiology Section
Prescription Drug Overdose Prevention Program
Injury and Behavioral Epidemiology Bureau
Epidemiology and Response Division**



This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of naloxone in the community.

This report is based on calendar quarters: Q1 is January-March of the calendar year.




Data for this report were drawn from several sources:

1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico.
2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies.
3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico.
4. The NM Department of Health Syringe Services Program for data on naloxone distributed via syringe exchange sites
5. The Behavioral Health Services Division in the Human Services Department for data on naloxone distributed through Office of Substance Abuse Prevention programs.

I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures

Totals

Year and Quarter	2017Q3	2018Q2	2018Q3	Quarterly % Change 2018Q2 vs 2018Q3	Quarterly % Change 2017Q3 vs 2018Q3
Total number of controlled substance patients	247,271	236,400	229,964	-2.7%	-7.0%
Number of patients receiving opioids	163,512	154,145	148,364	-3.8%	-9.3%
Number of opioid prescriptions filled (excluding buprenorphine/naloxone)	353,260	330,051	275,509	-16.5%	-22.0%
Number of buprenorphine/naloxone prescriptions filled	20,641	22,824	23,742	4.0%	15.0%
Number of high dose (>=90 MME/day) opioid prescriptions excluding buprenorphine/naloxone	43,250	39,331	37,558	-4.5%	-13.2%
Total MME of opioids filled - excluding buprenorphine/naloxone	323,328,200	296,877,603	288,065,589	-3.0%	-10.9%
Total MME/prescription-day	57	56	62	10.6%	8.5%
Number of patients receiving benzodiazepines	93,526	87,490	85,073	-2.8%	-9.0%
Number of benzodiazepine prescriptions filled	207,082	192,903	187,229	-2.9%	-9.6%
Number of high-dose(>=40 DME/day) benzodiazepine prescriptions filled	37,510	33,658	32,738	-2.7%	-12.7%
Total DME of benzodiazepines filled	115,005,327	103,503,807	99,752,073	-3.6%	-13.3%
Total DME/patient	1,230	1,183	1,173	-0.9%	-4.6%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

MME = Morphine Milligram Equivalent; reference at http://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf

DME = Diazepam Milligram Equivalent; reference at <http://archinte.jamanetwork.com/article.aspx?articleid=217249>, 2004

I. New Mexico Prescription Monitoring Program (PMP) Measures

Number of Patients with:

Year and Quarter	2017Q3	2018Q2	2018Q3	Quarterly % Change 2018Q2 vs 2018Q3	Quarterly % Change 2017Q3 vs 2018Q3
High dose opioids (>=90 MME/day)	15,491	14,065	13,186	-6.2%	-14.9%
High dose benzodiazepines (>=40 DME/day)	16,601	14,870	14,324	-3.7%	-13.7%
Opioids >=90 days and <90% of days in past 6 months	23,671	20,460	19,672	-3.9%	-16.9%
Opioids >=90% of days in past 6 months	31,124	31,031	30,730	-1.0%	-1.3%
Benzodiazepines >=90 days and <90% of days in past 6 months	26,181	23,123	22,290	-3.6%	-14.9%
Benzodiazepines >=90% of days in past 6 months	25,319	24,984	24,473	-2.0%	-3.3%
Overlapping prescriptions of opioids from different prescribers (>=10 days total overlap)	4,670	3,752	3,684	-1.8%	-21.1%
Overlapping prescriptions of benzodiazepines from different prescribers (>=10 days total overlap)	2,905	2,386	2,311	-3.1%	-20.4%
Concurrent opioid and benzodiazepines (>=10 days overlap)	22,913	19,767	18,655	-5.6%	-18.6%
High dose opioids (>=90 MME/day) plus benzodiazepines	4,441	3,643	3,418	-6.2%	-23.0%
Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months	3,420	2,627	2,715	3.3%	-20.6%
New Opioid Patients with at least 30 days of coverage in the past 3 months	3,790	3,403	3,120	-8.3%	-17.7%
New Benzodiazepine Patients with at least 30 days of coverage in the past 3 months	4,842	4,421	4,307	-2.6%	-11.0%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

I. New Mexico Prescription Monitoring Program (PMP) Measures


New Mexico Prescribers with at least 20 controlled substance patients:

Year and Quarter	2017Q3	2018Q2	2018Q3	Quarterly % Change 2018Q2 vs 2018Q3	Quarterly % Change 2017Q3 vs 2018Q3
Total active controlled substance prescribers	3,147	3,076	3,032	-1.4%	-3.7%
Prescribers with at least 50% high dose of opioid prescriptions, excluding treatment prescribers	53	62	59	-4.8%	11.3%
Prescribers with at least 50% high dose of benzodiazepine prescriptions	147	144	137	-4.9%	-6.8%
Prescribers with at least 25% of patients having concurrent opioids and benzodiazepines	25	24	17	-29.2%	-32.0%
Some PMP Use: Requested reports on at least 25% of patients estimated to require them	1,018	1,164	1,144	-1.7%	12.4%
Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances	738	551	579	5.1%	-21.5%
Number of Patients with PMP reports requested by practitioners	112,512	126,099	121,507	-3.6%	8.0%
% of Chronic opioid users with a PMP request in the past 3 months*	61.6%	66.3%	66.1%	-0.3%	7.3%
% of Chronic benzodiazepine users with a PMP request in the past 3 months*	38.8%	43.0%	42.1%	-2.2%	8.5%
% of New Opioid Patients with a PMP request in the past 3 months**	17.3%	19.3%	20.5%	6.5%	18.4%
% of New Benzodiazepine Patients with a PMP request in the past 3 months**	20.0%	23.0%	22.8%	-1.2%	13.7%

*Chronic users are those with at least 90 days of coverage in six months.

**New patients are those with more than 4 days of coverage in the quarter and none in the prior quarter.

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients



II. Medication Assisted Treatment (Buprenorphine/naloxone and methadone) Measures

Year and Quarter	2017Q3	2018Q2	2018Q3	Quarterly % Change 2018Q2 vs 2018Q3	Quarterly % Change 2017Q3 vs 2018Q3
Treatment (buprenorphine/naloxone) prescribers with at least 10 treatment patients	130	155	173	11.6%	33.1%
Buprenorphine/naloxone patients (>=10 days)	5,260	5,895	6,083	3.2%	15.6%
Buprenorphine/naloxone prescriptions filled	20,641	22,824	23,742	4.0%	15.0%
Total Practitioners with DATA Waiver	503	580	595	2.6%	18.3%
Nurse Practitioners and PA's with DATA Waiver	62	114	108	-5.3%	74.2%

Medicaid Methadone Treatment

Number of distinct individuals with methadone claims paid by NM Medicaid	4,764	5,152	5,338	3.6%	12.0%
Number of distinct NM Medicaid providers of methadone	11	11	11	0.0%	0.0%

Methadone Treatment Programs by Survey Date	3/2017	1/2018	3/2018	4/2018	8/2018
Number of Methadone Treatment Programs	15	15	16	16	16
Number of Methadone Treatment Patients in those Programs	5,531	5,275	5,662	6,076	6,258


DATA Waivered provider data are as of the last month of the quarter

Sources:

Buprenorphine/naloxone data: NM Prescription Monitoring Program

Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid

DATA Waivered providers: US DEA Diversion Control Division



III. Naloxone Distribution and Usage Measures

Year and Quarter	2017Q3	2018Q2	2018Q3	Quarterly % Change 2018Q2 vs 2018Q3	Quarterly % Change 2017Q3 vs 2018Q3
Total number of NM Government Program Naloxone Enrollments	1,423	1,408	2,420	71.9%	70.1%
Total Number of NM Naloxone Doses distributed	5,238	8,334	8,115	-2.6%	54.9%
Total Number of NM Reported Reversals	399	491	624	27.1%	56.4%

Year and Quarter	2017Q3	2018Q2	2018Q3	Quarterly % Change 2018Q2 vs 2018Q3	Quarterly % Change 2017Q3 vs 2018Q3
Pharmacies Presenting Medicaid Naloxone Claims	194	210	224	6.7%	15.5%
Number of Medicaid Naloxone Claims Processed	1,174	1,698	1,856	9.3%	58.1%
Number of Police Agencies Carrying Naloxone	73				

Some naloxone doses were given to organizations and may not have been distributed in that quarter.

Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once. Data on reversals are combined across several agencies and programs, and the definition of a reversal may vary.

An outpatient pharmacy could present claims in more than one quarter. The total number was obtained by counting each pharmacy once. There were 369 outpatient Pharmacies with a NM address in 2017 according to the Board of Pharmacy.

All law enforcement agencies have been contacted about naloxone training and use. The data reported reflect the number of agencies where at least some officers are carrying naloxone.

Sources: NM DOH Programs; NM HSD/BHSD Programs; NM Medicaid

